KUALA LUMPUR, June 4 (Bernama) — The Ministry of Health (MOH) would like to inform that the Drug Control Authority (DCA) Malaysia has granted a conditional registration for Ravida® Tablet 200mg (Ravidasvir Hydrochloride 200mg) in their 358th meeting on 4th June 2021. Malaysia is the first country in the world to approve the use of Ravida®, which is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. The product is manufactured by the Doppel Farmaceutici S.R.L, Italy with Pharmaniaga Manufacturing Berhad as the product registration holder in Malaysia.
HCV infection is considered as a public health issue whereby Malaysia is committed to the goal to eliminate HCV by 2030. However, the cost of screening and the currently available Direct Acting Antivirals (DAAs) are expensive and there is a need to search for alternative treatments and solutions. The National Strategic Plan for Hepatitis B & C 2019-2023 was developed by MOH to clearly strategise and to ensure the goal to eliminate hepatitis B and C is achievable.
